Dianthus Therapeutics (DNTH) Stock Forecast & Price Target

Compare

377 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

DNTH Analyst Ratings

Strong Buy

15 Buy

0 Hold

0 Sell

Based on 15 analysts giving stock ratings to

Dianthus

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

DNTH Stock 12 Month Forecast

Average Price Target

$67.58

▲(80.36% Upside)

Based on 15 Wall Street analysts offering 12 month price targets for Dianthus Therapeutics in the last 3 months. The average price target is $67.58 with a high forecast of $100.00 and a low forecast of $40.00. The average price target represents a 80.36% change from the last price of $37.47.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"$15","58":"$58","101":"$101","36.5":"$36.5","79.5":"$79.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$100.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":67.58,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$67.58</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$40.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,36.5,58,79.5,101],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.85,29.70769230769231,35.565384615384616,41.42307692307693,47.28076923076924,53.13846153846154,58.99615384615385,64.85384615384615,70.71153846153847,76.56923076923078,82.42692307692309,88.28461538461539,94.1423076923077,{"y":100,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.85,27.213846153846156,30.57769230769231,33.941538461538464,37.30538461538462,40.669230769230765,44.03307692307692,47.39692307692307,50.76076923076923,54.12461538461538,57.488461538461536,60.85230769230769,64.21615384615384,{"y":67.58,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.85,25.092307692307692,26.334615384615386,27.576923076923077,28.81923076923077,30.06153846153846,31.303846153846152,32.54615384615384,33.78846153846154,35.03076923076923,36.27307692307692,37.51538461538462,38.75769230769231,{"y":40,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":28.83,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.88,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.01,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.7,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.8,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.15,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.6,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.83,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.7,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.53,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.96,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.59,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.85,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$100.00

Average Price Target$67.58

Lowest Price Target$40.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$100

Buy

166.88%

Upside

Initiated

09/17/25

Dianthus Therapeutics (DNTH) Receives a New Rating from Roth MKM

William Maughan

Clear Street

$100

Buy

166.88%

Upside

Initiated

09/16/25

Dianthus initiated with a Buy at Clear StreetDianthus initiated with a Buy at Clear Street

Matt Phipps

William Blair

―

Buy

―

Reiterated

09/13/25

William Blair Keeps Their Buy Rating on Dianthus Therapeutics (DNTH)we reiterate our Outperform rating: MaGic:Impressive Claseprubart Efficacy; Muted Reaction From Overblown ANA Safety Considerations a Buying Opportunity

Laura Chico

Wedbush

$42→$44

Buy

17.43%

Upside

Reiterated

09/12/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Alex Thompson CFA

Stifel Nicolaus

$52→$65

Buy

73.47%

Upside

Reiterated

09/12/25

Dianthus price target raised to $65 from $52 at StifelDianthus price target raised to $65 from $52 at Stifel

Joel Beatty

Robert W. Baird

$50→$67

Buy

78.81%

Upside

Reiterated

09/09/25

Dianthus price target raised to $67 from $50 at BairdDianthus price target raised to $67 from $50 at Baird

Ryan Deschner

Raymond James

$56→$63

Buy

68.13%

Upside

Reiterated

09/09/25

Dianthus price target raised to $63 from $56 at Raymond JamesDianthus price target raised to $63 from $56 at Raymond James

Yaron Werber

TD Cowen

―

Buy

―

Reiterated

09/08/25

TD Cowen Sticks to Its Buy Rating for Dianthus Therapeutics (DNTH)Given more convenient self-admin SC Q2W dosing and no black box warning, we reiterate conviction in claseprubart in gMG, CIDP and MMN.

Rami Katkhuda

LifeSci Capital

$45→$65

Buy

73.47%

Upside

Reiterated

09/08/25

Promising Phase II Results and Market Potential Drive Buy Rating for Dianthus TherapeuticsThis morning, Dianthus (Nasdaq: DNTH) reported posive topline results from the Phase II MaGic study, evaluang claseprubart in AChR+ generalized myasthenia gravis paents.

Swayampakula Ramakanth

H.C. Wainwright

$40

Buy

6.75%

Upside

Reiterated

09/08/25

Promising Phase 2 Results and Market Potential Drive Buy Rating for Dianthus Therapeutics' Claseprubart

Gavin Clark-Gartner

Evercore ISI

$50→$72

Buy

92.15%

Upside

Reiterated

09/08/25

Dianthus price target raised to $72 at Evercore after 'bull case outcome'Dianthus price target raised to $72 at Evercore after 'bull case outcome'

Maury Raycroft

Jefferies

$51

Buy

36.11%

Upside

Reiterated

09/08/25

Promising Clinical Data and Strategic Plans Support Buy Rating for Dianthus TherapeuticsWe believe the gMG data derisks claseprubart (active C1s mAb) w/ path fwd to a pot'l registrational study in gMG (pot'ly fast ~13wk MG-ADL endpt) and derisks efficacy+dosing for programs in CIDP (ph.III interim responder analysis in 2H26) and MMN (ph.II topline 2H26). DNTH is planning for an EOP2 mtg w/ FDA to get alignment on pivotal design, and co plans to explore 300mg Q2W and 600mg monthly dosing (based on encouraging OLE data). Although gMG is viewed as a competitive mkt, we believe: 1) claseprubart's profile is highly competitive, not just vs complement inhs, but also vs FcRns, based on sustained MG-ADL reductions vs rebounds w/ the gMG mkt will grow to incl more 1L pts w/ more self-admin tx options like DNTH's claseprubart.

Yatin Suneja

Guggenheim

$92

Buy

145.53%

Upside

Reiterated

09/05/25

Dianthus Therapeutics (DNTH) Gets a Buy from GuggenheimGuggenheim analyst Yatin Suneja reiterated a Buy rating and $92.00 price target on Dianthus Therapeutics (NASDAQ: DNTH).

Pete Stavropoulos

Cantor Fitzgerald

―

Buy

―

Reiterated

08/22/25

Cantor Fitzgerald Sticks to Its Buy Rating for Dianthus Therapeutics (DNTH)Cantor Fitzgerald analyst Pete Stavropoulos reiterated an Overweight rating on Dianthus Therapeutics (NASDAQ: DNTH).

Trevor Allred

Oppenheimer

$52

Buy

38.78%

Upside

Reiterated

08/08/25

Oppenheimer Sticks to Its Buy Rating for Dianthus Therapeutics (DNTH)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$100

Buy

166.88%

Upside

Initiated

09/17/25

Dianthus Therapeutics (DNTH) Receives a New Rating from Roth MKM

William Maughan

Clear Street

$100

Buy

166.88%

Upside

Initiated

09/16/25

Dianthus initiated with a Buy at Clear StreetDianthus initiated with a Buy at Clear Street

Matt Phipps

William Blair

―

Buy

―

Reiterated

09/13/25

Laura Chico

Wedbush

$42→$44

Buy

17.43%

Upside

Reiterated

09/12/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Alex Thompson CFA

Stifel Nicolaus

$52→$65

Buy

73.47%

Upside

Reiterated

09/12/25

Dianthus price target raised to $65 from $52 at StifelDianthus price target raised to $65 from $52 at Stifel

Joel Beatty

Robert W. Baird

$50→$67

Buy

78.81%

Upside

Reiterated

09/09/25

Dianthus price target raised to $67 from $50 at BairdDianthus price target raised to $67 from $50 at Baird

Ryan Deschner

Raymond James

$56→$63

Buy

68.13%

Upside

Reiterated

09/09/25

Dianthus price target raised to $63 from $56 at Raymond JamesDianthus price target raised to $63 from $56 at Raymond James

Yaron Werber

TD Cowen

―

Buy

―

Reiterated

09/08/25

Rami Katkhuda

LifeSci Capital

$45→$65

Buy

73.47%

Upside

Reiterated

09/08/25

Swayampakula Ramakanth

H.C. Wainwright

$40

Buy

6.75%

Upside

Reiterated

09/08/25

Promising Phase 2 Results and Market Potential Drive Buy Rating for Dianthus Therapeutics' Claseprubart

Gavin Clark-Gartner

Evercore ISI

$50→$72

Buy

92.15%

Upside

Reiterated

09/08/25

Dianthus price target raised to $72 at Evercore after 'bull case outcome'Dianthus price target raised to $72 at Evercore after 'bull case outcome'

Maury Raycroft

Jefferies

$51

Buy

36.11%

Upside

Reiterated

09/08/25

Yatin Suneja

Guggenheim

$92

Buy

145.53%

Upside

Reiterated

09/05/25

Dianthus Therapeutics (DNTH) Gets a Buy from GuggenheimGuggenheim analyst Yatin Suneja reiterated a Buy rating and $92.00 price target on Dianthus Therapeutics (NASDAQ: DNTH).

Pete Stavropoulos

Cantor Fitzgerald

―

Buy

―

Reiterated

08/22/25

Cantor Fitzgerald Sticks to Its Buy Rating for Dianthus Therapeutics (DNTH)Cantor Fitzgerald analyst Pete Stavropoulos reiterated an Overweight rating on Dianthus Therapeutics (NASDAQ: DNTH).

Trevor Allred

Oppenheimer

$52

Buy

38.78%

Upside

Reiterated

08/08/25

Oppenheimer Sticks to Its Buy Rating for Dianthus Therapeutics (DNTH)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Dianthus Therapeutics

1 Month

xxx

Success Rate

4/4 ratings generated profit

Average Return

+30.53%

reiterated a xxx

rating 14 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 100.00% of your transactions generating a profit, with an average return of +30.53% per trade.

3 Months

xxx

Success Rate

6/7 ratings generated profit

Average Return

+35.06%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 85.71% of your transactions generating a profit, with an average return of +35.06% per trade.

1 Year

Yaron WerberTD Cowen

Success Rate

6/6 ratings generated profit

Average Return

+65.17%

reiterated a buy rating 11 days ago

Copying Yaron Werber's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +65.17% per trade.

2 Years

xxx

Success Rate

7/7 ratings generated profit

Average Return

+78.63%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +78.63% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DNTH Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, DNTH has received 34 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. DNTH average Analyst price target in the past 3 months is 67.58.

Each month's total comprises the sum of three months' worth of ratings.

DNTH Financial Forecast

DNTH Earnings Forecast

Next quarter’s earnings estimate for DNTH is -$0.89 with a range of -$1.03 to -$0.68. The previous quarter’s EPS was -$0.88. DNTH beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 51.30% of the time in the same period. In the last calendar year DNTH has Outperformed its overall industry.

DNTH Sales Forecast

Next quarter’s sales forecast for DNTH is $576.00K with a range of $0.00 to $2.28M. The previous quarter’s sales results were $193.00K. DNTH beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 45.64% of the time in the same period. In the last calendar year DNTH has Outperformed its overall industry.

DNTH Stock Forecast FAQ

What is DNTH’s average 12-month price target, according to analysts?

Based on analyst ratings, Dianthus Therapeutics’s 12-month average price target is 67.58.

What is DNTH’s upside potential, based on the analysts’ average price target?

Dianthus Therapeutics has 80.36% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is DNTH a Buy, Sell or Hold?

Dianthus Therapeutics has a consensus rating of Strong Buy which is based on 15 buy ratings, 0 hold ratings and 0 sell ratings.

What is Dianthus Therapeutics’s price target?

The average price target for Dianthus Therapeutics is 67.58. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $100.00 ,the lowest forecast is $40.00. The average price target represents 80.36% Increase from the current price of $37.47.

What do analysts say about Dianthus Therapeutics?

Dianthus Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of DNTH?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Dianthus Therapeutics (DNTH) Stock Forecast & Price Target

DNTH Analyst Ratings

DNTH Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Dianthus Therapeutics

DNTH Analyst Recommendation Trends

DNTH Financial Forecast

DNTH Earnings Forecast

DNTH Sales Forecast

DNTH Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts